You are here

MOLECULES FOR HEALTH, INC.

Company Information
Address
800 E. LEIGH STREET SUITE 206-7
RICHMOND, VA 23219 1534
United States



Information

UEI: N/A

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Ribonucleotide Reductase Inhibitors for Restenosis

    Amount: $225,698.00

    DESCRIPTION (provided by applicant): Coronary artery disease is a major health problem and the leading cause of premature death in the US. Percutaneous coronary intervention with stenting is the prima ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  2. Radical Scavengers for Brain Ischemia Reperfusion injury

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The goal of this proposal is to determine the potential of two MFH free radical scavenging compounds, Didox and Imidate, to protect brain tissue from stroke inj ...

    SBIRPhase I2003Department of Health and Human Services National Institutes of Health
  3. Novel Cancer Drugs to Prevent Doxorubicin Toxicity

    Amount: $107,767.00

    DESCRIPTION (provided by applicant): Doxorubicin, an anthracycline drug, is effective against numerous solid and hematological cancers, but cardiotoxicity limits its usefulness. The spe ...

    SBIRPhase I2001Department of Health and Human Services National Institutes of Health
  4. Ribonucleotide Reductase Inhibitors for AIDS Therapy

    Amount: $749,713.00

    We will develop a series of Ribonucleotide reductase inhibitors for the treatment of retrovirus (AIRibonucleotide reductase catalyzes the reductive conversion of ribonucleotides to deoxyribonucleotida ...

    SBIRPhase II1998Department of Health and Human Services
  5. Ribonucleotide Reductase Inhibitors for AIDS Therapy

    Amount: $99,794.00

    We will develop a series of Ribonucleotide reductase inhibitors for the treatment of retrovirus (AIRibonucleotide reductase catalyzes the reductive conversion of ribonucleotides to deoxyribonucleotida ...

    SBIRPhase I1995Department of Health and Human Services
  6. NEW DRUGS TO PREVENT REPERFUSION ISCHEMIA INJURY

    Amount: $499,963.00

    THIS RESEARCH IS BASED ON THE THESIS THAT OXYGEN-FREE RADICALS CONTRIBUTE IN A SIGNIFICANT WAY TO THE DELETERIOUS ASPECT OF REPERFUSION AFTER A TISSUE OR ORGAN IS DEPRIVED OFOXYGEN AND FLOW IS RE-INIT ...

    SBIRPhase II1993Department of Health and Human Services
  7. POTENTIAL NEW TOPICAL ANTI-PSORIASIS AGENTS

    Amount: $49,998.00

    PSORIASIS AFFECTS APPROXIMATELY 2 PERCENT OF THE U. S. POPULATION AND MOST PRESENT TREATMENTS ARE EITHER POTENTIALLY HARMFUL OR ENTAIL DIFFICULT AND/OR UNPLEASANT PROCEDURES. THEREFORE NEW AGENTS ARE ...

    SBIRPhase I1991Department of Health and Human Services
  8. NEW DRUGS TO PREVENT REPERFUSION ISCHEMIA INJURY

    Amount: $49,000.00

    N/A

    SBIRPhase I1990Department of Health and Human Services
  9. POLYHYDROXYPHENYL-CONJUGATES FOR ANTITUMOR ACTIVITY

    Amount: $49,962.00

    THE REDUCTIVE CONVERSION OF RIBONUCLEOTIDES TO DEOXYRIBONUCLEOTIDES, CATALYZED BY RIBONUCLEOTIDE REDUCTASE,IS A CRUCIAL AND RATE-LIMITING REACTION IN THE DNA BIOSYNTHETIC PATHWAY, AND REPRESENTS A LOG ...

    SBIRPhase I1989Department of Health and Human Services
  10. POLYHYDROXYPHENYL DERIVATIVES DESIGNED FOR ANTITUMOR ACTIVITY

    Amount: $50,000.00

    THE REDUCTIVE CONVERSION OF RIBONUCLEOTIDES TO DEOXYRIBONUCLEOTIDES, CATALYZED BY RIBONUCLEOTIDE REDUCTASE,IS A CRUCIAL AND RATE-LIMITING REACTION IN THE DNA BIOSYNTHETIC PATHWAY. THIS REACTION, THERE ...

    SBIRPhase I1987Department of Health and Human Services
US Flag An Official Website of the United States Government